Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths



14 day average Hospitalizations



7 day Average Deaths



Average test positivity past 7 days 11.7%, Up 0.6% from last week
Cases have increased from last week.
At public test sites in California we have seen an increase from an average of 14% positivity to 30% over the last 3-4 weeks
There is also a rise in COVID concentration in wastewater in California
14 day average hospitalizations have increased by 100% over the last month
7 day average deaths remain at low levels.
For the week starting 11/27, 91% of molecular tests resulted in less than 24 hours and 97% of tests resulted in less than 48 hours.

Dec 8 2022 with data as of Dec 6, 2022.
https://covid19.ca.gov/state-dashboard/ **https://testing.covid19.ca.gov/**
COVID-19 Cases Dashboard v2.0 - CA OpeNn Data | Tableau Pub

Daily new confirmed COVID-19 cases per million people

Our World in Data

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.



Hospitalizations across the US (increase by 25%) and California are rising (increase by 100%)
COVID-19 cases are rising again in Japan, Hong Kong and Australia and in parts of Europe.
Waning pop. immunity likely contributed to rise of cases in addition to new immune evasive variants
Highlighting the importance of booster vaccination.

Variant update





Increases in BQ.1.1, BQ.1, XBB, and BN.1, rate of growth starting to slow for BQs.

Everything else decreasing or no change

BQ.1 and BQ.1.1 represent a majority of sequenced cases in US and in California..

BQ variants have immune evasive properties rendering use of monoclonal antibodies to be ineffective
(both are resistant to Bebtelovimab)

CH1.1

- CH.1.1 = BM.4.1.1.1.1 = **BA.2.75.3**.4.1.1.1.1
- Lineage has the largest growth advantage worldwide right now, 40-60% growth advantage
- Increasing in prevalence in countries that don’t have as much BQ.1, so hard to know what will happen once it spreads to countries with high levels of BQ.1.1
- Similar immune evasiveness compared to BQ.1.1
- Less than 0.6% of cases

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid

- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date



Figure 4. Percentage of Influenza Admissions at Kaiser Permanente Northern California Facilities, 2017-2023 Season to Date



Figure 3. Percentage of Influenza-like Illness Visits Among Patients Seen by California Sentinel Providers, 2017–2023 Season to Date